Data Readout

Oruka's ORKA-001 hits 63.5% skin clearance; durability data due in H2

The IL-23p19 antibody cleared skin fully in 40 of 63 psoriasis patients at Week 16, and Oruka now must show that response holds through Week 52 with twice-yearly or less-frequent dosing.

By AppliedXLJuly 13, 2026Trial NCT07090330

Executive Summary

Oruka Therapeutics disclosed that its IL-23p19 antibody ORKA-001 met the primary endpoint of its Phase 2a psoriasis study, with a majority of patients reaching complete skin clearance at Week 16.
The company's own hypothesis, that infrequent dosing can sustain that response, has not yet been tested; longer-term follow-up data are due later this year.
No other IL-23p19 program has reached Phase 2 in this indication, so the interim result stands without a same-mechanism, same-stage comparator, while approved IL-23p19 antibodies set the efficacy and dosing-frequency bar it aims to beat.
The proof-of-concept bar is cleared; the value of the program now depends on whether reduced dosing frequency preserves that response over a full year.

The result

Oruka Therapeutics, Inc. said 40 of 63 evaluable patients in the EVERLAST-A trial achieved a 100% reduction in Psoriasis Area and Severity Index (PASI) score at Week 16, the trial's registered primary endpoint. The company described the safety profile as consistent with the known class of IL-23p19 inhibitors. The trial, a randomized, double-blind, placebo-controlled Phase 2a study enrolling 80 patients with moderate-to-severe plaque psoriasis, tests ORKA-001 against placebo before randomizing responders to one of two maintenance arms: dosing every six months, or induction-only dosing to test how long clearance persists without further treatment. That design is the mechanism behind the company's stated goal of once- or twice-yearly dosing, compared with currently approved IL-23p19 antibodies dosed four to six times a year. NCT07090330+1

Probability of Success

Endpoint Met49%

Completes88%

Clinical Significance5%

Regulatory64%

What the readout still owes

The Week 16 result answers only the first half of the trial's question, whether ORKA-001 can clear skin at all. The trial's own design shifts the harder test to Week 52, when the maintenance arms report whether patients dosed every six months, or dosed only once at induction, keep that response. Oruka said it expects to report Week 28 data for all patients and 52-week follow-up for a subset in the second half of 2026, alongside data from the Phase 2b EVERLAST-B trial expected in 2027. The registry's primary completion date moved from September 2026 to April 1, 2026, a change recorded alongside the trial's shift to Active, not recruiting status on March 17, 2026. NCT07090330+1

The competitive frame

IL-23p19 inhibitors have become preferred first-line therapy in moderate-to-severe plaque psoriasis given their efficacy and safety record, and currently approved agents in the class deliver full clearance in fewer than half of patients after four months of dosing four to six times per year, according to the company. No other industry trial pairs the IL-23p19 target with a Phase 2 stage in this indication, so the 63.5% Week 16 clearance rate has no same-mechanism, same-stage comparator on record. The closest analogs in the broader competitive field, including risankizumab, brodalumab, and tildrakizumab programs, work through different IL-23 or IL-17 pathway targets and sit mostly in Phase 3 or Phase 4 settings. The bar ORKA-001's durability data need to clear is not statistical significance, since the primary endpoint is already met, but whether reduced-frequency dosing preserves the clearance rate that approved four-to-six-times-yearly regimens achieve in less than half of patients. Oruka

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.